Clinical Trials Directory

Trials / Sponsors / Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals

Industry · 10 registered clinical trials.

StatusTrialPhaseStarted
WithdrawnEvaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cance
Pancreatic Cancer Stage IV
Phase 22024-08-15
WithdrawnCPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colo
C04.588.274.476.411.307
Phase 12023-03-30
CompletedTo Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroqui
Sarcoma, Clear Cell
Phase 1 / Phase 22021-09-01
TerminatedEfficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R
Relapsed/Refractory Acute Myeloid Leukemia
Phase 32018-11-12
CompletedStudy Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastati
Pancreatic Cancer Metastatic
Phase 32018-11-09
WithdrawnSafety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrom
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase 22016-01-01
WithdrawnSafety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Phase 22014-01-01
TerminatedPhase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Cancer
Phase 22013-06-01
TerminatedA Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Pa
Cancer, Pancreatic Cancer, Pancreatic Carcinoma
Phase 1 / Phase 22009-05-01
CompletedA Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
Advanced Cancer, Metastatic Cancer, Lymphoma
Phase 12008-08-01